CBG protects memory in a rat model of schizophrenia
Cannabigerol improves MK-801-induced long-term recognition memory deficit in male rats through cortical TrkB-R signaling independently of changes in BDNF.
AI Summary
This preclinical study found that repeated treatment with cannabigerol (CBG) prevented the long-term recognition-memory deficit caused by MK-801 in male rats. MK-801 is used to model some schizophrenia-related cognitive problems by blocking NMDA receptors. Memory was assessed with a novel object recognition task, and the abstract reports no sample size or effect-size measurements.
The memory benefit was not linked to restoring reduced BDNF levels. Instead, combined CBG and MK-801 treatment increased TrkB receptor messenger RNA in the medial prefrontal cortex, suggesting that CBG may support memory through BDNF-independent TrkB signaling. These findings support further research into CBG for cognitive impairment, but they do not show that CBG improves memory or treats schizophrenia in people.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Brain blood-flow reductions in acute anorexia follow a cortical hierarchy
CBD showed limited adaptive-functioning differences versus placebo in boys…
Resilience linked to depression outcomes and THC positivity
Explore More Research
Stay informed about the latest cannabis science.